Evonik Industries AG Company Overview
Evonik Industries AG is a German specialty chemicals company headquartered in Essen, Germany. The present Evonik group was created in 2007 through the renaming of RAG-Beteiligungs-AG, although its chemical heritage extends through predecessor businesses including Goldschmidt and Degussa. Evonik develops additives, specialty polymers, silicas and silanes, active oxygens, crosslinkers, amino acids, pharmaceutical and personal-care ingredients, catalysts and other performance chemicals. Its technologies serve coatings, adhesives, construction, automotive and transportation, consumer goods, nutrition, pharmaceuticals, energy, electronics and industrial manufacturing. Evonik generated €14.1 billion in sales in 2025 and is increasingly concentrating its operating portfolio on differentiated specialty-chemical businesses where application knowledge, process technology and customer-specific formulation can support attractive margins.
The company's current positioning reflects a substantial shift away from its former divisional structure. Since April 2025, its principal chemical businesses have been organized into Custom Solutions and Advanced Technologies, complemented by Infrastructure activities. Custom Solutions concentrates businesses where formulation expertise, customer intimacy and tailored solutions are central to differentiation, while Advanced Technologies groups businesses where proprietary process technology, production efficiency and technological scale are stronger competitive factors. This model is designed to give individual business lines greater operational accountability while retaining access to Evonik's common technology platforms, research capabilities and global manufacturing network.
Evonik Industries AG Company Snapshot
|
Parameter |
Information |
|---|---|
|
Company Name |
Evonik Industries AG |
|
Headquarters |
Essen, Germany |
|
Present Company Established |
2007 |
|
Chief Executive Officer |
Christian Kullmann, Chairman of the Executive Board |
|
Ownership |
Public company; RAG-Stiftung remains the anchor shareholder |
|
Primary Listing |
Frankfurt Stock Exchange, Prime Standard |
|
Ticker |
EVK |
|
FY2025 Revenue |
€14.1 billion |
|
FY2025 Adjusted EBITDA |
€1.874 billion |
|
Employees |
Approximately 31,000 |
|
Global Market Presence |
Active in more than 100 countries |
|
Production Presence |
Production plants in 27 countries across six continents |
|
Operating Segments |
Custom Solutions; Advanced Technologies; Infrastructure |
Evonik Industries AG Business Structure and Competitive Position
Evonik reorganized its chemical activities into two differentiated operating models in April 2025. Custom Solutions contains Additives and Health & Care activities, including coating, polyurethane, oil and other performance additives alongside care solutions and healthcare technologies. Advanced Technologies comprises Animal Nutrition, Organics and Inorganics, covering technologies such as methionine, crosslinkers, high-performance polymers, silicas, silanes and active oxygens. The Infrastructure segment combines site-related infrastructure activities with the Oxeno C4 chemicals business. The structure places individual business lines closer to operating responsibility and allocates capital according to their distinct economics rather than managing all specialty-chemical operations through a common divisional model.
Evonik's competitive position is strongest where relatively small quantities of specialty chemistry determine customer-product performance or where proprietary processing knowledge creates barriers to substitution. Additives require formulation knowledge and application testing across coatings, polyurethane foams and lubricants; high-performance polymers depend on polymer chemistry and customer qualification; Animal Nutrition combines fermentation and chemical processing with nutritional expertise; and Health Care integrates pharmaceutical chemistry with regulated manufacturing. Advanced Technologies also benefits from process optimization in continuous, high-volume specialty manufacturing. Across these areas, Evonik combines application laboratories, production know-how, intellectual property and technical collaboration with customers rather than competing primarily on commodity-scale output.
Evonik Industries AG Business Segments and Revenue Analysis
|
Business Segment |
Annual Sales |
EBITDA |
Principal Activities |
|---|---|---|---|
|
Custom Solutions |
€5.49 billion |
€909 million adjusted EBITDA |
Additives, Care Solutions and Health Care |
|
Advanced Technologies |
€5.97 billion |
€944 million adjusted EBITDA |
Animal Nutrition, Organics and Inorganics |
|
Infrastructure |
Reported within Evonik's Infrastructure/Other reporting framework |
Infrastructure and associated results reported separately from the two chemical segments |
Marl and Wesseling infrastructure services and Oxeno C4 chemicals |
Custom Solutions
Custom Solutions combines businesses where customer-specific functionality and formulation know-how are particularly important. Its Additives activities encompass coating additives, coatings and adhesive resins, additives for polyurethane applications, oil additives and interface-performance technologies. Health & Care includes personal-care and pharmaceutical technologies. End markets range from paints, coatings and adhesives to mobility, consumer durables, lubricants, cosmetics and pharmaceuticals. Differentiation is based on application expertise, formulation support and the ability to influence performance using relatively small quantities of specialized chemistry. In 2025, Custom Solutions generated €5.49 billion in sales and €909 million in adjusted EBITDA, equivalent to a 16.6% adjusted EBITDA margin.
Advanced Technologies
Advanced Technologies groups businesses where proprietary chemistry, process efficiency and technological scale play a greater role. Animal Nutrition supplies amino-acid and nutritional technologies, while Organics includes crosslinkers and high-performance polymers and Inorganics incorporates Smart Effects and Active Oxygens. Applications include animal feed, membranes, additive manufacturing, specialty foams, coatings, chemical processing and industrial oxidants. Production economics and process optimization are particularly important because several activities use continuous, technically demanding manufacturing systems. The segment generated €5.97 billion of revenue and €944 million of adjusted EBITDA in 2025, giving an adjusted EBITDA margin of 15.8%.
Infrastructure
Infrastructure bundles the site-related infrastructure operations associated principally with Evonik's Marl and Wesseling chemical locations and includes the Oxeno C4 chemicals business. Its activities differ substantially from Evonik's formulation-led specialty operations: chemical-park infrastructure covers services required to operate large integrated manufacturing complexes, while Oxeno produces C4-based intermediates and associated chemicals. The segment therefore combines industrial infrastructure economics with process-intensive chemical production. Its strategic role has increasingly been separated from Evonik's core specialty businesses, particularly through the creation of SYNEQT for the Marl and Wesseling infrastructure operations.
Evonik Industries AG Global Manufacturing and Geographic Footprint
Evonik operates production plants in 27 countries across six continents and conducts business in more than 100 countries. Germany remains a major manufacturing and technology center, with significant operations in locations including Marl, Wesseling, Hanau and other chemical-industry clusters. Marl Chemical Park is Evonik's largest production location and contains a broad network of integrated chemical and service infrastructure. Antwerp is another major European multi-user facility supporting activities including Animal Nutrition, crosslinkers, Smart Effects and Active Oxygens.
North America provides an important production base for specialty chemicals and life-science manufacturing. Mobile, Alabama, is Evonik's largest chemical manufacturing site in North America and is integrated into the company's global methionine value chain. Mobile complements methionine-related production in Antwerp and Singapore, providing regional production of the key intermediate methyl mercaptan and strengthening supply security across the Americas.
Asia-Pacific combines major manufacturing platforms with proximity to rapidly expanding industrial and consumer markets. Singapore is particularly important for Animal Nutrition, while China supports multiple specialty-chemical technologies and end-user industries. This geographically distributed manufacturing model enables Evonik to combine centralized process and technology development with regional production. For qualification-intensive or logistics-sensitive products, local manufacturing can shorten supply chains and improve technical responsiveness; for process-intensive businesses such as methionine, globally integrated production also provides redundancy and operational flexibility.
Evonik Industries AG Mergers, Divestitures and Portfolio Transformation
Evonik's recent transformation has focused primarily on portfolio simplification and organizational redesign rather than large-scale acquisitions. In August 2024, the company completed the sale of its superabsorbents business to International Chemical Investors Group. The business, which generated €892 million of sales in 2023, included five production locations in Germany and the United States and represented the second major step in Evonik's planned exit from the former Performance Materials division.
Organizational transformation accelerated in 2025. Evonik introduced Custom Solutions and Advanced Technologies from April 1, replacing its previous major chemical divisions with business models differentiated by customer-specific formulation requirements and process-technology economics. The company also combined its former Silica and Silanes business lines into Smart Effects from January 2025. Infrastructure activities at Marl and Wesseling were subsequently bundled into SYNEQT GmbH, which began operating as an independent entity at the start of 2026. Evonik additionally divested its betaines joint-venture business in Indonesia in October 2025.
Portfolio actions continued in 2026. Evonik sold selected pharmaceutical-ingredient production assets in Hanau to ProChem Group while retaining its strategic focus on higher-value Health Care activities. Separately, the company announced a US$100 million multiyear modernization program for its drug-substance manufacturing site in Lafayette, Indiana, targeting upgraded reactors, automation and manufacturing reliability. These actions illustrate Evonik's broader approach: dispose of businesses or assets with weaker strategic fit while directing capital toward differentiated specialty platforms in healthcare, additives and technologically demanding materials.
Related USDAnalytics Market Research
Examines fumed silica used as a rheology modifier, reinforcing filler, anti-caking agent and performance additive across silicones, coatings, adhesives, pharmaceuticals and industrial formulations.
Examines precipitated silica used in tires, rubber products, oral care, food, coatings and industrial applications for reinforcement, absorption, flow control and functional performance.
Examines functional additives used to control rheology, wetting, dispersion, foam, surface appearance, durability and application performance across architectural and industrial coating formulations.
Examines crosslinking chemicals used in coatings, adhesives, elastomers, composites and polymer systems to improve mechanical strength, chemical resistance, thermal stability and durability.
Examines chemical additives used in automotive and industrial lubricants to improve viscosity, wear protection, oxidation stability, friction control, cleanliness and equipment performance.
Examines individual amino acids used across animal nutrition, food, pharmaceuticals, dietary nutrition and specialty formulations for nutritional, metabolic and functional applications.
Examines selective ion-conducting membranes used in electrolysis, fuel cells, water treatment, electrodialysis and energy applications requiring controlled ionic transport and chemical stability.
High Performance Polyamides Market
Examines advanced polyamide materials used across automotive, electronics, industrial and specialty applications requiring thermal resistance, mechanical strength, chemical durability and lightweight performance.